The Oncology Institute, Inc. TOI Intravenous (IV) drug costs — Direct costs

Similar metrics at other companies

BTSGPharmacy Solutions — Other Direct Costs

$197.78M+9.5%

SNDXBiopharmaceutical Cancer Therapeutics — Cost Of Product Sales

$2.63M+198%

LBR

LBRXClinical Trial — Direct Research And Development Expenses

$1.18M-88.8%

MEDPDirect Costs — Total direct costs

$198.27M+11.5%

CACIInternational — Direct costs

$33.98M+29.8%

LBR

LBRXPreclinical And Other Direct Expenses — Direct Research And Development Expenses

$501K—

Questions, answered.

What is The Oncology Institute, Inc.'s intravenous (IV) drug costs — direct costs?

The Oncology Institute, Inc. (TOI) reported intravenous (IV) drug costs — direct costs of $29.77M in Q1 2026.

What does intravenous (IV) drug costs — direct costs mean?

This metric represents the total direct expenditures incurred by the oncology segment specifically related to the procurement and administration of intravenous pharmaceutical therapies. It captures the primary variable costs associated with delivering specialized cancer treatments to patients within the clinical setting. Monitoring this figure allows stakeholders to assess the direct cost burden of drug therapies relative to the volume of patient services provided.